Evidence map›Paper›PMID 41390238›Full record

ReviewJournal of neurology, neurosurgery, and psychiatry2026

Lecanemab appropriate use recommendations for clinical practice in the UK.

Catherine J Mummery, Jill Rasmussen, Dan Blackburn, Elizabeth Coulthard, R Rhys Davies, Rachel Dorsey, Nick C Fox, Akram A Hosseini, Chineze Ivenso, Matthew Jones and 13 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of neurology, neurosurgery, and psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Catherine J MummeryNational Hospital for Neurology and Neurosurgery, University College London, London, England, UK cath.mummery@nhs.net.ORCID http://orcid.org/0000-0002-6739-0803
Jill RasmussenPrimary Care Specialist Dementia, Mental Health and Learning Disability, Surrey, UK.ORCID http://orcid.org/0000-0003-4365-0428
Dan BlackburnNeuroscience, School of Medicine and Population Health, The University of Sheffield, Sheffield, UK.ORCID http://orcid.org/0000-0001-8886-1283
Elizabeth CoulthardBristol Medical School, University of Bristol, Bristol, Bristol, UK.ORCID http://orcid.org/0000-0002-0017-9595
R Rhys DaviesThe Walton Centre NHS Foundation Trust, Liverpool, England, UK.ORCID http://orcid.org/0000-0002-8157-078X
Rachel DorseyImperial College London, London, England, UK.
Nick C FoxNational Hospital for Neurology and Neurosurgery and Queen Square Institute of Neurology, University College London, London, England, UK.ORCID http://orcid.org/0000-0002-6660-657X
Akram A HosseiniNottingham University Hospitals NHS Trust, Nottingham, England, UK.ORCID http://orcid.org/0000-0003-0133-9842
Chineze IvensoAneurin Bevan University Health Board, Newport, Wales, UK.ORCID http://orcid.org/0009-0003-3690-2698
Matthew JonesManchester Centre for Clinical Neurosciences, Salford Royal Hospital, Salford, England, UK.
Sean P KennellyDepartment of Medical Gerontology, School of Medicine, Trinity College Dublin, Dublin, Ireland.ORCID http://orcid.org/0000-0002-3721-0197
Christopher KippsUniversity Hospital Southampton NHS Foundation Trust, Southampton, England, UK.ORCID http://orcid.org/0000-0002-5205-9712
Daniel LashleyUniversity Hospitals Plymouth NHS Trust, Plymouth, Plymouth, UK.ORCID http://orcid.org/0009-0002-6758-0540
Graham MackayAberdeen Royal Infirmary, Aberdeen, Scotland, UK.ORCID http://orcid.org/0000-0002-4316-2320
Rashi NegiMidlands Partnership NHS Foundation Trust, Lichfield, England, UK.ORCID http://orcid.org/0009-0006-4918-3647
Ramin NilforooshanSurrey and Borders Partnership NHS Foundation Trust, Surrey, England, UK.ORCID http://orcid.org/0000-0001-9801-183X
Peter Anthony PassmoreQueen's University Belfast, Belfast, Northern Ireland, UK.ORCID http://orcid.org/0000-0002-5738-6800
Richard PerryImperial College London, London, England, UK.ORCID http://orcid.org/0000-0002-4536-9018
Vanessa RaymontOxford University, Oxford, Oxfordshire, UK.ORCID http://orcid.org/0000-0001-8238-4279
James Benedict RoweCambridge Centre for Frontotemporal Dementia, University of Cambridge, Cambridge, England, UK.ORCID http://orcid.org/0000-0001-7216-8679
Tom C RussCentre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, Scotland, UK.ORCID http://orcid.org/0000-0001-9797-2188
John-Paul TaylorTranslational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, England, UK.ORCID http://orcid.org/0000-0001-7958-6558
Alistair BurnsOxford Health NHS Foundation Trust, Oxford, England, UK.ORCID http://orcid.org/0000-0002-9837-0645

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lecanemab is an anti-amyloid monoclonal antibody, recently approved in the UK as a treatment for mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD) in adults who are apolipoprotein E ε4 gene (

Indexed as

Alzheimer DiseaseAntibodies, Monoclonal, HumanizedCognitive DysfunctionAmyloid beta-PeptidesApolipoprotein E4HumansMagnetic Resonance ImagingUnited KingdomAmyloid beta-PeptidesAntibodies, Monoclonal, HumanizedApolipoprotein E4ALZHEIMER'S DISEASEAMYLOIDAPOLIPOPROTEINSMEMORYTREATMENT OUTCOME

Identifiers

PMID41390238
PMCPMC13151530

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.